Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Dec 15, 2020; 12(12): 1428-1442
Published online Dec 15, 2020. doi: 10.4251/wjgo.v12.i12.1428
Published online Dec 15, 2020. doi: 10.4251/wjgo.v12.i12.1428
Variable | Disease-free survival | Overall survival | ||||
Univariate P value | Multivariate | Univariate P value | Multivariate | |||
HR (95%CI) | P value | HR (95%CI) | P value | |||
Age (< 60 vs ≥ 60 yrs) | 0.492 | 0.770 (0.255-1.618) | 0.492 | 0.729 | 0.621 (0.314-1.245) | 0.177 |
Sex (female vs male) | 0.493 | 0.773 (0.375-1.626) | 0.493 | 0.678 | 0.906 (0.442-1.812) | 0.783 |
Location (colon vs rectum) | 0.353 | 0.216 (0.102-1.231) | 0.153 | 0.346 | 0.291 (0.054-1.154) | 0.082 |
cT stage (T4a vs T4b) | 0.127 | 2.423 (0.604-9.836) | 0.258 | 0.206 | 2.611 (0.752-9.054) | 0.128 |
cN stage (N0 vs N+) | 0.127 | 0.690 (0.139-3.014) | 0.157 | 0.102 | 0.336 (0.094-1.087) | 0.078 |
Tumor grade (WD/MD vs PD) | 0.335 | 0.503 (0.098-1.936) | 0.413 | 0.423 | 0.840 (0.247-2.500) | 0.765 |
CEA (≤ 5 ng/mL vs > 5 ng/mL) | 0.418 | 1.422 (0.614-3.391) | 0.383 | 0.528 | 1.219 (0.581-2.622) | 0.602 |
Neoadjuvant chemotherapy (FOLFOX vs Capecitabine) | 0.142 | 3.549 (0.944-7.467) | 0.082 | 0.117 | 2.846 (0.860-8.715) | 0.158 |
Radiation dose (< 50 Gy vs ≥ 50 Gy) | 0.351 | 0.291 (0.054-1.154) | 0.182 | 0.327 | 2.525 (0.347-5.843) | 0.221 |
Radiation-surgery interval (≤ 9 wk vs > 9 wk) | 0.086 | 1.236 (0.792-5.276) | 0.097 | 0.106 | 2.064 (0.589-7.062) | 0.167 |
ypT stage (ypT3-4 vs ypT0-2) | 0.237 | 2.484 (0.744-5.691) | 0.636 | 0.097 | 2.150 (0.820-6.123) | 0.121 |
ypN stage (ypN+ vs ypN0) | 0.005 | 3.120 (1.245-8.357) | 0.017a | 0.073 | 1.771 (0.435-6.255) | 0.405 |
Lymphovascular invasion (positive vs negative) | 0.363 | 2.503 (0.724-7.788) | 0.141 | 0.175 | 3.046 (0.961-9.081) | 0.069 |
Perineural invasion (positive vs negative) | 0.072 | 2.649 (0.869-8.976) | 0.087 | 0.091 | 1.222 (0.323-4.078) | 0.757 |
Resection margin (positive vs negative) | 0.001 | 3.549 (1.004-12.747) | 0.014a | 0.013 | 4.136 (1.675-10.829) | 0.001a |
Pathological response (non-pCR vs pCR) | 0.045 | 2.560 (1.186-6.013) | 0.042a | 0.031 | 2.977 (1.420-6.369) | 0.003a |
- Citation: Huang CM, Huang CW, Ma CJ, Tsai HL, Su WC, Chang TK, Huang MY, Wang JY. Outcomes of neoadjuvant chemoradiotherapy followed by radical resection for T4 colorectal cancer. World J Gastrointest Oncol 2020; 12(12): 1428-1442
- URL: https://www.wjgnet.com/1948-5204/full/v12/i12/1428.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i12.1428